- Correction
- Open access
- Published:
Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis
Diabetology & Metabolic Syndrome volume 14, Article number: 68 (2022)
The Original Article was published on 18 October 2021
Correction to: Diabetol Metab Syndr (2021) 13:110 https://doi.org/10.1186/s13098-021-00733-5
Following publication of the original article [1], the Table 2 reports incorrect data for some of the studies included in the analysis:
-
1.
In the study by Davies et al. (row 3), the dose of liraglutide should read 3.0Â mg instead of 0.3Â mg.
-
2.
In the study by Greenway et al. (row 6), it should read Naltrexone 16.0 mg + bupropion instead of Naltrexone + bupropion 16.0 mg, and Naltrexone 32.0 mg + bupropion instead of Naltrexone + bupropion 32.0 mg.
-
3.
In the study by O’Neil et al. (row 9) it should read Lorcaserin 10 mg BID instead of Orlistat 120.mg BID, and Lorcaserin 10 mg QD instead of Orlistat 120.mg QD.
The authors apologize for such mistakes. The data and the script files used in the analysis are available as Additional files 1, 2 and 3 to all readers.
Reference
Salari N, Jafari S, Darvishi N, Valipour E, Mohammadi M, Mansouri K, Shohaimi S. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr. 2021;13:110. https://doi.org/10.1186/s13098-021-00733-5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The article to which this update relates has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1186/s13098-023-01048-3
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Salari, N., Jafari, S., Darvishi, N. et al. Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr 14, 68 (2022). https://doi.org/10.1186/s13098-022-00838-5
Published:
DOI: https://doi.org/10.1186/s13098-022-00838-5